Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 15;8(6):3051-3060.
doi: 10.1039/c7ra10807a. eCollection 2018 Jan 12.

Enhanced osteogenic activity of Ti alloy implants by modulating strontium configuration in their surface oxide layers

Affiliations

Enhanced osteogenic activity of Ti alloy implants by modulating strontium configuration in their surface oxide layers

Zhengjiang Xu et al. RSC Adv. .

Abstract

To guarantee the long-term stability of an orthopaedic implant, non-degradable surface coatings with the ability to selectively release bioactive drugs or ions are especially desirable. In this study, SrO-TiO2 composite coatings were deposited on the surface of Ti alloys, whose release behavior of bioactive Sr ions was modulated by the Sr configurations, either interstitial atoms in solid solution (Ti y Sr2-2y O2) or strontium titanate (SrTiO3). A perfect linear relationship between the amount of the released Sr ions and the Sr content in the coating was observed. Among the SrO-doped TiO2 coatings, the 20% SrO-TiO2 coating where Sr existed in both forms of Ti y Sr2-2y O2 and SrTiO3 not only promoted proliferation of bone cells but also enhanced their osteogenic differentiation, which was proved to be related to its Sr release behavior. However, overdosing with 30% SrO only resulted in one single Sr configuration (SrTiO3) and an inferior osteogenic function. This study suggests that Sr configurations of both interstitial atoms of the solid solution and SrTiO3 can realize the selective release of Sr, but they possibly have different effects on the biological functions and other properties including corrosion resistance.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. XRD patterns of the TiO2 and SrO–TiO2 coatings.
Fig. 2
Fig. 2. SEM images of the TiO2 (A), 10% SrO–TiO2 (B), 20% SrO–TiO2 (C) and 30% SrO–TiO2 (D) coatings.
Fig. 3
Fig. 3. Potentiodynamic polarization curves of TiO2, 10% SrO–TiO2, 20% SrO–TiO2, 30% SrO–TiO2 coatings.
Fig. 4
Fig. 4. The surface morphology of the TiO2 (A), 10% SrO–TiO2 (B), 20% SrO–TiO2 (C), 30% SrO–TiO2 (D) coatings after immersion in 2× SBF for 14 days.
Fig. 5
Fig. 5. XRD patterns of the TiO2 coating and the SrO–TiO2 coatings soaked in 2× SBF for 14 days.
Fig. 6
Fig. 6. Concentrations of Sr ions released from TiO2, 10% SrO–TiO2, 20% SrO–TiO2, 30% SrO–TiO2 coatings after immersion in culture medium for 3, 6 and 9 days.
Fig. 7
Fig. 7. Observation of cell initial attachment on the coatings, fluorescence microscope images (A) and SEM (B) of cells cultured on Ti6Al4V, TiO2, 10% SrO–TiO2, 20% SrO–TiO2, 30% SrO–TiO2 for 24 h. Scale bar, 20 μm.
Fig. 8
Fig. 8. The proliferation and ALP activity and of rBMSCs cultured on the Ti6Al4V, TiO2, 10% SrO–TiO2, 20% SrO–TiO2, 30% SrO–TiO2 coatings at day 14.
Fig. 9
Fig. 9. Quantitative PCR analysis of the cells cultured on TiO2, 10% SrO–TiO2, 20% SrO–TiO2, 30% SrO–TiO2 coatings for 7 and 14 days, house-keeping gene GAPDH was used as an internal control. *Statistically significant difference among different samples (p < 0.05).
Fig. 10
Fig. 10. SEM and EDS of crystals precipitated on its surface after incubation with cells for 24 h (A), the ratio of anatase and rutile phase in the composite coatings (B), quantitative PCR analysis of the cells cultured on TiO2, 10% SrO–TiO2, 20% SrO–TiO2, 30% SrO–TiO2 coatings dissolution products (C).

Similar articles

Cited by

References

    1. Andreini C. Bertini I. Cavallaro G. Holliday G. L. Thornton J. M. J. Biol. Inorg Chem. 2008;13:1205–1218. doi: 10.1007/s00775-008-0404-5. - DOI - PubMed
    1. Budimir A. Acta Pharm. 2011;61:1–14. doi: 10.2478/v10007-011-0006-6. - DOI - PubMed
    1. Mouriño V. Cattalini J. P. Boccaccini A. R. J. R. Soc., Interface. 2012;9:401–419. doi: 10.1098/rsif.2011.0611. - DOI - PMC - PubMed
    1. Hamdy N. A. T. Rheumatology. 2009;48:9–13. doi: 10.1093/rheumatology/kep274. - DOI - PubMed
    1. Hu H. Zhang W. Qiao Y. Jiang X. Liu X. Ding C. Acta Biomater. 2012;8:904–915. doi: 10.1016/j.actbio.2011.09.031. - DOI - PubMed